Skip to main content
The Society of Thoracic Surgeons

User account menu

  • Log in
Menu

Main navigation

  • FIGHT
    • Coping with Cancer
      • Just Diagnosed
      • In Treatment
      • In Remission
      • Survivorship
    • Cancer Information
      • Bladder Cancer
      • Blood Cancer
      • Breast Cancer
      • Head and Neck Cancer
      • Lung Cancer
      • Melanoma
      • Other
      • Latest Featured Content
      • The Archives
      • Other Resources
    • Find Clinical Trials
    • Glossary
      • Cancer FAQs
  • EDUCATE
    • Current Patient Education Video Series
      • ASCO Lung Roundtable
      • Bladder Cancer Video Library
      • Cancer Information for the Latino Community
      • Case Based Panel Discussions
      • Clinical Trials Experiences Through Storytelling
      • Coronavirus and Covid 19 in the Cancer Community
      • East Asian Lung Cancer Video Library
      • HPV Advances - A Patient Education Program
      • Head and Neck Cancer News and Updates ASCO / ESMO
      • Lung Cancer Video Library - English
      • Lung Cancer Video Library - Spanish
      • Lung OncTalk
      • Patient Education Ambassador Program
      • Targeted Therapies Patient Forum - English
      • Targeted Therapies Patient Forum - Spanish
      • Testing and Early Diagnosis
    • GRACE Podcasts
    • Video Library
      • English
      • Spanish
      • Mandarin
  • PARTICIPATE
    • Community Forum
      • Bladder Cancer
      • Blood Cancer
      • Brain Cancer
      • Breast Cancer
      • Colorectal Cancer
      • Gall Bladder and Bile Duct Cancer (Cholangiocarcinoma)
      • Head and Neck Cancer
      • Kidney Cancer
      • Lung Cancer
      • Melanoma
      • Member Updates
      • General Forums
      • Ask A Question
    • Get Involved
      • Memorials and Tributes
      • Volunteer Opportunities
  • ABOUT CancerGRACE
    • GRACE NEWS AND INFO
      • Contact Us
      • How (and Why) to Use GRACE
      • GRACE Public Disclosure Documentation
    • About GRACE
      • Mission
      • Opportunities
      • Terms of Use
      • Our Supporters 2020
    • Our Team
      • Faculty
      • Staff and Board
    • Partnerships
      • GRACE and Clinical Care Options Patient Tools
      • Varian Partner Page 2020
      • Takeda Oncology Partnership Page 2020
      • Lilly Oncology Partner Page
  • DONATE
    • Why Give to GRACE
      • More Ways to Give
      • Corporate Giving Programs
      • Gifts of Stock or Securities
      • Shop and Search for the Cause
      • Create a Tribute
      • Create Your Own Fundraiser
      • Shop with GRACE

Breadcrumb

  1. Home
  2. Forums
  3. PET scan tumor metastisis vs an imflammatory response - 1272462

OAK trial with Tecentriq (atezolizumab) is positive: How a "me too" result may change the landscape in advanced NSCLC

Article

With positive trials of two immune checkpoint inhibitors, Opdivo (nivolumab) and Keytruda (pembrolizumab), in second line NSCLC and compared with Taxotere (docetaxel), it should come as a surprise to nobody that another checkpoint inhibitor, Tecentriq (atezolizumab) has also proven superior to Taxotere in the OAK trial of previously treated NSCLC patients, as reported in a press release today.

  • Read more about OAK trial with Tecentriq (atezolizumab) is positive: How a "me too" result may change the landscape in advanced NSCLC
  • 2 comments

Are There Clinically Significant Distinctions Between PD-1 and PD-L1?

Video

Dr. Jack West, Swedish Cancer Institute, compares the mechanism of action, efficacy and toxicity of PD-1 and PD-L1 inhibitors.

  • Read more about Are There Clinically Significant Distinctions Between PD-1 and PD-L1?

Immunotherapy for First Line Therapy of Advanced NSCLC

Video

Dr. Eddie Garon considers the data on immunotherapies for first line treatment of advanced NSCLC and whether we are likely to use these agents instead of or in combination with standard chemotherapy soon.

  • Read more about Immunotherapy for First Line Therapy of Advanced NSCLC

What is the Optimal Duration of Immunotherapy?

Video

UCLA Med Center's Dr. Eddie Garon discusses the open question of the optimal duration of ongoing treatment with immunotherapy for lung cancer.

  • Read more about What is the Optimal Duration of Immunotherapy?

Time to Response to Immunotherapy and the Concept of Pseudoprogression

Article

Dr. Eddie Garon reviews the pattern of response to immunotherapy in lung cancer, along with the concept of "pseudoprogression".

  • Read more about Time to Response to Immunotherapy and the Concept of Pseudoprogression

Immunotherapy Combinations: Is this the Future for Treating Lung Cancer?

Article

As we learn more about immunotherapy for lung cancer, combinations with multiple immunotherapy agents are being explored. Medical oncologist Dr. Eddie Garon considers whether combinations are likely to emerge as the leading immunotherapy approach.

  • Read more about Immunotherapy Combinations: Is this the Future for Treating Lung Cancer?

Clinical Trials of Immune Checkpoint Inhibitors as First Line Therapy for Advanced NSCLC

Article

Dr. Jack West summarizes the rationale for testing immune checkpoint inhibitors as a first line treatment for patients with advanced NSCLC and highlights details of two trials testing this question.

  • Read more about Clinical Trials of Immune Checkpoint Inhibitors as First Line Therapy for Advanced NSCLC

Do Clinical Characteristics Alter Your Enthusiasm for Immune Checkpoint inhibitors?

Article

Drs. Leora Horn, Ben Solomon, & Jack West assess whether clinical factors such as being a never-smoker or having a driver mutation (EGFR, ALK, etc.) reliably predict minimal benefit from immunotherapy agents.

  • Read more about Do Clinical Characteristics Alter Your Enthusiasm for Immune Checkpoint inhibitors?

Should PD-L1 be Used as a Biomarker for Immunotherapy in Lung Cancer?

Article

Dr. Eddie Garon, UCLA, reviews the controversial question of whether PD-L1 expression is a reliable enough biomarker to be used to select patients to receive or not receive immune checkpoint inhibitor therapy in lung cancer.

  • Read more about Should PD-L1 be Used as a Biomarker for Immunotherapy in Lung Cancer?

Should PD-L1 Testing Be Ordered at Diagnosis or After Progression?

Article

Drs. Leora Horn, Ben Solomon, & Jack West consider the factors that might lead us to favor testing for PD-L1 at initial workup of a patient with advanced NSCLC or after progression.

  • Read more about Should PD-L1 Testing Be Ordered at Diagnosis or After Progression?

Pagination

  • Page 1
  • Next page ››
Subscribe to atezolizumab

Stay In touch

NEWSLETTER SIGN UP

MISSIONDONATEDISCLAIMERRESOURCES

Copyright © 2021 Global Resource for Advancing Cancer Education
Site by Freelock

  • Log in
  • FIGHT
    • Coping with Cancer
      • Just Diagnosed
      • In Treatment
      • In Remission
      • Survivorship
    • Cancer Information
      • Bladder Cancer
      • Blood Cancer
        • Blood Cancer Video Library 2021
      • Breast Cancer
      • Head and Neck Cancer
      • Lung Cancer
      • Melanoma
      • Other
      • Latest Featured Content
      • The Archives
      • Other Resources
    • Find Clinical Trials
    • Glossary
      • Cancer FAQs
  • EDUCATE
    • Current Patient Education Video Series
      • ASCO Lung Roundtable
      • Bladder Cancer Video Library
      • Cancer Information for the Latino Community
      • Case Based Panel Discussions
      • Clinical Trials Experiences Through Storytelling
      • Coronavirus and Covid 19 in the Cancer Community
      • East Asian Lung Cancer Video Library
      • HPV Advances - A Patient Education Program
      • Head and Neck Cancer News and Updates ASCO / ESMO
      • Lung Cancer Video Library - English
      • Lung Cancer Video Library - Spanish
      • Lung OncTalk
      • Patient Education Ambassador Program
      • Targeted Therapies Patient Forum - English
      • Targeted Therapies Patient Forum - Spanish
      • Testing and Early Diagnosis
    • GRACE Podcasts
    • Video Library
      • English
      • Spanish
      • Mandarin
  • PARTICIPATE
    • Community Forum
      • Bladder Cancer
      • Blood Cancer
      • Brain Cancer
      • Breast Cancer
      • Colorectal Cancer
      • Gall Bladder and Bile Duct Cancer (Cholangiocarcinoma)
      • Head and Neck Cancer
      • Kidney Cancer
      • Lung Cancer
      • Melanoma
      • Member Updates
      • General Forums
      • Ask A Question
    • Get Involved
      • Memorials and Tributes
      • Volunteer Opportunities
  • ABOUT CancerGRACE
    • GRACE NEWS AND INFO
      • Contact Us
      • How (and Why) to Use GRACE
      • GRACE Public Disclosure Documentation
    • About GRACE
      • Mission
      • Opportunities
      • Terms of Use
      • Our Supporters 2020
    • Our Team
      • Faculty
      • Staff and Board
    • Partnerships
      • GRACE and Clinical Care Options Patient Tools
      • Varian Partner Page 2020
      • Takeda Oncology Partnership Page 2020
      • Lilly Oncology Partner Page
  • DONATE
    • Why Give to GRACE
      • More Ways to Give
      • Corporate Giving Programs
      • Gifts of Stock or Securities
      • Shop and Search for the Cause
      • Create a Tribute
      • Create Your Own Fundraiser
      • Shop with GRACE